Loading...
skip to Main Content

Register for #ILC2021 with early fees & enjoy savings of up to EUR 450!

So how about upgrading your bike? 🚵‍♂️🚴‍♂️🚴 Too much time inside calls for some outdoor exercise.

➡️Register now: https://easl.eu/ILC2021-reg

Tell us below what you’ll do with your early-fee savings.

CHB patients routinely undergo screening for #HCC, but the efficacy of screening is unclear.

@gnioannou, @FengSu_MD & co. reported that screening by ultrasound and/or serum AFP was associated with a reduction in HCC-related mortality.

Read: https://bit.ly/3nZsMjR
#LiverTwitter

Webcast description

The ability to detect and trace SARS-CoV-2 throughout the population is fundamental to the success of any COVID-19 management strategy, but the different tests available have advantages and disadvantages with crucial implications for how screening programmes are managed and administered.

In this webcast, three world-renowned experts, Professor Jean-Michel Pawlotsky, Professor Jon Deeks and Professor Mario Mondelli, discuss the current state of COVID-19 diagnostics. Opening with an explanation of virological markers and their development over the course of infection, and the capabilities of different testing modalities, the experts discuss key challenges such as reliability and limited sensitivity in asymptomatic patients, and the practicalities of evaluating diagnostic tools in real-world use.

In doing so, the experts evaluate how current diagnostic capabilities can be best used to establish risk, identify disease in individuals and to track the spread of SARS-CoV-2 within the population.

Moderator: Jean-Michel Pawlotsky
Panel:

  • Prof. Jon Deeks,
  • Prof. Mario Mondelli,
  • Prof. Jean-Michel Pawlotsky

Learning objectives

  • Understand the development of virological markers during the infection
  • Apprehend the modalities of the different tests available
  • Learn more about the reliability and limited sensitivity of the tests in asymptomatic patients
  • Understand how to establish risk, identify disease and track the spread of SARS-CoV-2 within the population

Target audience

  • General practitioners
  • Hepatologists
  • Health care professionals
  • Clinical researchers and scientists

Register for #ILC2021 with early fees & enjoy savings of up to EUR 450!

So how about upgrading your bike? 🚵‍♂️🚴‍♂️🚴 Too much time inside calls for some outdoor exercise.

➡️Register now: https://easl.eu/ILC2021-reg

Tell us below what you’ll do with your early-fee savings.

CHB patients routinely undergo screening for #HCC, but the efficacy of screening is unclear.

@gnioannou, @FengSu_MD & co. reported that screening by ultrasound and/or serum AFP was associated with a reduction in HCC-related mortality.

Read: https://bit.ly/3nZsMjR
#LiverTwitter

Back To Top